



Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-023-02668-y>, published online 17 November 2023.

<https://doi.org/10.1038/s41591-024-02910-1>

Published online: 11 March 2024

Lindsay B. Kilburn , Dong-Anh Khuong-Quang , Jordan R. Hansford , Daniel Landi, Jasper van der Lugt , Sarah E. S. Leary , Pablo Hernáiz Driever , Simon Bailey , Sébastien Perreault, Geoffrey McCowage, Angela J. Waanders, David S. Ziegler , Olaf Witt, Patricia A. Baxter, Hyoung Jin Kang , Timothy E. Hassall, Jung Woo Han , Darren Hargrave , Andrea T. Franson , Michal Yalon Oren, Helen Toledano, Valérie Larouche , Cassie Kline , Mohamed S. Abdelbaki, Nada Jabado , Nicholas G. Gottardo , Nicolas U. Gerber , Nicholas S. Whipple, Devorah Segal , Susan N. Chi, Liat Oren, Enrica E. K. Tan, Sabine Mueller , Izzy Cornelio, Lisa McLeod, Xin Zhao, Ashley Walter, Daniel Da Costa, Peter Manley, Samuel C. Blackman, Roger J. Packer & Karsten Nysom 

In the version of the article initially published, in the third paragraph of the “RAPNO criteria (secondary endpoints)” section, the text now reading “Thirteen (17.1%) patients initially had a best overall response of PD...” originally read “Thirty-one patients initially had PD...”. This has been corrected in the HTML and PDF versions of the article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024